Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Advanced Squamous Cell Lung Cancer
NCT01491633Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in squamous cell carcinoma of the lung (LSCC), sponsored by Dana-Farber Cancer Institute. Started Sep 2011; status: terminated.
02
Drugs
dasatinib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT01491633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01491633.